Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CGT4255 |
| Synonyms | |
| Therapy Description |
CGT4255 is an EGFR-sparing ERBB2 (HER2) inhibitor that may inhibit the growth of tumor cells harboring ERBB2 (HER2) mutations (Cancer Res (2025) 85 (8_Supplement_1): 5623). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CGT4255 | CGT 4255|CGT-4255 | HER2 Inhibitor 45 | CGT4255 is an EGFR-sparing ERBB2 (HER2) inhibitor that may inhibit the growth of tumor cells harboring ERBB2 (HER2) mutations (Cancer Res (2025) 85 (8_Supplement_1): 5623). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07361562 | Phase I | CGT4255 | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |